Phase 3 Topline Results Announced
On August 19, 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (V940/mRNA-4157), an individualized mRNA-based neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab) as adjuvant treatment for patients with completely resected, high-risk Stage IIB-IV cutaneous melanoma.[1]
According to the companies, the randomized Phase 3 study enrolled 1,137 patients and met its primary endpoint of recurrence-free survival (RFS) as well as a key secondary endpoint of distant metastasis-free survival (DMFS). At the prespecified interim analysis, the combination was reported to provide statistically significant and clinically meaningful improvements in both endpoints compared with pembrolizumab alone.[1]
Moderna and Merck described INTerpath-001 as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy.[1] If confirmed by the complete dataset, this represents an important milestone for a therapeutic approach that has largely remained in early-stage and smaller clinical studies.
A Personalized Approach to Cancer Immunotherapy
Unlike a conventional vaccine produced as the same formulation for many people, intismeran autogene is designed individually based on the molecular characteristics of each patient's tumor.
Tumor sequencing is used to identify patient-specific mutations, from which candidate neoantigens, abnormal antigens that may distinguish tumor cells from normal cells, are selected. Intismeran consists of synthetic mRNA encoding up to 34 selected neoantigens, with the goal of generating or expanding T-cell responses against the patient's tumor.[2,3]
In INTerpath-001, this individualized therapy is being tested in combination with pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, rather than as a standalone treatment. The study focuses on the adjuvant setting: patients have already undergone complete surgical resection but remain at elevated risk of disease recurrence.[2]
Earlier evidence came from the randomized Phase IIb KEYNOTE-942 study. At five years of follow-up, intismeran plus pembrolizumab was associated with a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared with pembrolizumab alone. However, overall survival data remained immature, with only a limited number of deaths observed.[3]
Encouraging - but Full Phase 3 Data Are Still Needed
The Phase 3 announcement is encouraging, particularly because the trial reportedly met prespecified efficacy endpoints in a large randomized study. However, it is important to distinguish a positive topline announcement from a complete analysis of the clinical data.
As of the initial announcement, Moderna and Merck had not publicly disclosed key numerical Phase 3 results such as hazard ratios, confidence intervals, event numbers, Kaplan-Meier survival curves, or detailed subgroup analyses. Overall survival also remains under follow-up.[1]
For this reason, the magnitude of the Phase 3 benefit cannot yet be independently assessed from publicly available information. Detailed results will be particularly important for determining not only whether the difference is statistically significant, but how large and clinically relevant the benefit is for patients.
The companies have indicated that complete data will be presented at an upcoming international medical meeting.[1]
Why It Matters for Research
Beyond the clinical result itself, this milestone reinforces interest in the broader research ecosystem surrounding neoantigens, tumor immunology, and personalized immunotherapy.
Relevant cell models, including tumor cell lines, engineered cell models, patient-derived cells, organoids, and tumor-immune co-culture systems, can support studies of antigen presentation, tumor-immune interactions, T-cell responses, and mechanisms of sensitivity or resistance to immunotherapy.[4]
As individualized neoantigen strategies expand into additional tumor types, such models may become increasingly valuable for connecting genomic and computational predictions with experimentally validated tumor biology and immune responses.
Looking Ahead
The INTerpath-001 announcement does not yet establish that individualized mRNA cancer therapy improves overall survival, nor does success in melanoma guarantee similar outcomes in other cancers.
Nevertheless, reaching a positive Phase 3 topline readout represents a notable step forward for both individualized neoantigen therapy and therapeutic mRNA technology in oncology.
The next important question is no longer simply whether this approach can reach late-stage clinical development, but how substantial the benefit is, which patients are most likely to benefit, and whether the strategy can be successfully extended to other cancers.
References
- Merck & Co., Inc. and Moderna, Inc. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients With Completely Resected Stage IIB-IV Melanoma. Press release. August 19, 2026.
- ClinicalTrials.gov. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001/INTerpath-001). ClinicalTrials.gov Identifier: NCT05933577.
- Khattak MA, Carlino MS, Meniawy T, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. Journal of Clinical Oncology. Published June 1, 2026. doi:10.1200/JCO-26-00835.
- Zhou Z, Pang Y, Ji J, et al. Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies. Nature Reviews Immunology. 2024;24:18-32. doi:10.1038/s41577-023-00896-4.
